Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients

Bladder cancer is the ninth most commonly diagnosed cancer in the world and fth in the USA and Canada (1,2). Patients presenting with bladder cancer are initially treated with transurethral resection and specimens are graded and staged.